Non-silencing selectable marker genes and methods of use
View Patent ↗Provided are nucleic acids and expression vectors having a non-silencing selectable marker gene, and methods of using the same. A subject expression vector includes an expression cassette and a non-silencing selectable marker gene. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) includes an increased A/T content relative to a corresponding wild type nucleotide sequence. In some cases, the non-silencing selectable marker gene provides for drug resistance for prokaryotic cells, and includes a nucleotide sequence that (i) encodes a drug selectable marker protein; (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) has an A/T content in a range of from 52% to 70%.
1. An expression vector for transgene expression in eukaryotic cells, comprising:
(a) an expression cassette comprising a transgene operably linked to a promoter functional in eukaryotic cells; and
(b) a non silencing selectable marker gene that comprises a nucleotide sequence that: (i) encodes a drug selectable marker protein that provides resistance for prokaryotic cells to kanamycin; (ii) is operably linked to a promoter functional in prokaryotic cells, (iii) comprises a T:A ratio in a range of from 1.2to 1.9and an A/T content of 54% or more, and (iv) has 85% or more nucleotide sequence identity with the sequence set forth in any one of SEQ ID NOs: 3 and 4.
2. The expression vector according to claim 1 , wherein said A/T content is in a range of from 54% to 68%.
3. The expression vector according to claim 1 , wherein the nucleotide sequence encoding the drug selectable marker protein comprises 2 or fewer instances of the following Polymerase II (Pol II) pause site: TTATT.
4. The expression vector according to claim 1 , wherein the nucleotide sequence encoding the drug selectable marker protein does not comprise any of the following Polymerase II (Pol II) pause sites: TTTATT, TTTTTTTCCCTTTTTT (SEQ ID NO: 17), and AAAAAAGGGAAAAAAA (SEQ ID NO: 18).
5. The expression vector according to claim 1 , wherein the transgene is operably linked to a promoter functional in one or more cells selected from: mammalian cells, rodent cells, primate cells, and human cells.
6. The expression vector according to claim 1 , wherein the transgene comprises a nucleotide sequence encoding an RNA selected from: a translated RNA, a non-coding RNA, an antisense RNA, a microRNA, an shRNA, and an siRNA.
7. The expression vector according to claim 1 , wherein the transgene comprises a nucleotide sequence encoding a protein.
8. A method of expressing a transgene in a eukaryotic cell, the method comprising:
introducing into a eukaryotic cell an expression vector according to claim 1 , wherein the expression vector provides for expression of the transgene once present in the eukaryotic cell.
9. The method according to claim 8 , wherein the eukaryotic cell is in culture in vitro.
10. The method according to claim 8 , wherein the eukaryotic cell is in culture ex vivo.
11. The method according to claim 8 , wherein the eukaryotic cell is in vivo.
12. The method according to claim 8 , wherein the eukaryotic cell is a mammalian cell.
13. The method according to claim 8 , wherein said introducing comprises administering to an individual a formulation comprising the expression vector.
14. The method according to claim 13 , wherein said administering comprises systemic administration.
15. The method according to claim 13 , wherein the individual is a mouse or a human.
16. The method according to claim 8 , wherein the transgene comprises a nucleotide sequence encoding an RNA selected from: a translated RNA, a non-coding RNA, an antisense RNA, a microRNA, an shRNA, and an siRNA.
17. The method according to claim 8 , wherein the transgene comprises a nucleotide sequence encoding a protein.
18. An expression vector for transgene expression in eukaryotic cells, comprising:
(a) an expression cassette comprising a transgene operably linked to a promoter functional in eukaryotic cells; and
(b) a non silencing selectable marker gene comprising a nucleotide sequence that (i) encodes a drug selectable marker protein that provides resistance for prokaryotic cells to kanamycin, (ii) is operably linked to a promoter functional in prokaryotic cells, and (iii) comprises the nucleotide sequence set forth in any of SEQ ID NOs: 3 and 4.
19. The expression vector according to claim 18 , wherein the transgene is operably linked to a promoter functional in one or more cells selected from: mammalian cells, rodent cells, primate cells, and human cells.
20. The expression vector according to claim 18 , wherein the transgene comprises a nucleotide sequence encoding an RNA selected from: a translated RNA, a non-coding RNA, an antisense RNA, a microRNA, an shRNA, and an siRNA.
21. The expression vector according to claim 18 , wherein the transgene comprises a nucleotide sequence encoding a protein.
22. A method of expressing a transgene in a eukaryotic cell, the method comprising:
introducing into a eukaryotic cell an expression vector according to claim 18 , wherein the expression vector provides for expression of the transgene once present in the eukaryotic cell.
23. The method according to claim 22 , wherein the eukaryotic cell is in culture in vitro.
24. The method according to claim 22 , wherein the eukaryotic cell is in culture ex vivo.
25. The method according to claim 22 , wherein the eukaryotic cell is in vivo.
26. The method according to claim 22 , wherein the eukaryotic cell is a mammalian cell.
27. The method according to claim 22 , wherein said introducing comprises administering to an individual a formulation comprising the expression vector.
28. The method according to claim 27 , wherein said administering comprises systemic administration.
29. The method according to claim 27 , wherein the individual is a mouse or a human.
30. The method according to claim 22 , wherein the transgene comprises a nucleotide sequence encoding an RNA selected from: a translated RNA, a non-coding RNA, an antisense RNA, a microRNA, an shRNA, and an siRNA.
31. The method according to claim 22 , wherein the transgene comprises a nucleotide sequence encoding a protein.